5月28日电，被FDA叫停基因疗法试验，Rocket Pharma股价盘中暴跌逾60%。

Group 1 - The core point of the article is that Rocket Pharma's gene therapy trial has been halted by the FDA, leading to a significant drop in the company's stock price, which fell over 60% during intraday trading [1] Group 2 - The FDA's decision to stop the gene therapy trial indicates potential regulatory challenges for the biotechnology sector, particularly for companies involved in similar research and development [1] - The sharp decline in Rocket Pharma's stock price reflects investor concerns regarding the viability of its gene therapy programs and the overall market sentiment towards biotech stocks following regulatory setbacks [1] - This incident may prompt other companies in the industry to reassess their clinical trial strategies and regulatory compliance measures to avoid similar outcomes [1]